Navigation Links
UW-Madison spinoff Pedrus finds more to business planning than good science

Pedrus Pharma, a University of Wisconsin-Madison spinout that has sped to the finals in the Governor's Business Plan Contest, may put a stop to the annual flu vaccine hoopla, among other things.

Founders Curtis Brandt and Hansi Dean, both UW-Madison researchers, are developing two drugs based on antiviral peptides discovered in Brandt's lab.......

Full article >>> ration papers were just filed last month."

The company


Pedrus, an acronym of Peptide Drug Strategies, is a drug-discovery company. After taking its first two drugs through trials, it may go on to develop others.

"It turns out that bigger pharmaceutical companies are basically wanting to see a compound get either to the start of phase one or through the phase one clinical ......

Full article >>> st 4-5 years of the company, which we hope will keep the costs down," Brandt said.

The pre-clinical trials, and all of the other development that Pedrus Pharma will be doing with its drug compounds, will need major funding. With eligibility as a company established, Brandt and Dean decided to apply for the Governor's Business Plan Contest because it gave them extra impetus to come up with......

Full article >>>
'"/>

Source:wistechnology.com By Katy Williams 04/18/05


Related biology technology :

1. UW-Madison to receive $125M for bioenergy research center
2. Three finalists named for UW-Madison CIO
3. UW-Madison launches new high-speed research network
4. UW-Madison approves new research institute
5. UW-Madison dean predicts bio-economy will fuel Wisconsin
6. Scott Converse, UW-Madison School of Business, on the innovation mind-set
7. Scott Converse, UW-Madison School of Business, on IT workforce development
8. UW-Madisons Beebe wins scientific award
9. UW-Madison MBA program ranked among best for investment return
10. UW-Madison gets $333,000 for biofuels research
11. UW-Madison enters Kauffman grant competition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):